Background {#Sec1}
==========

Polycystic ovary syndrome (PCOS) is a disease that mostly occurs in women of childbearing age. It is characterized by excessive androgen secretion and persistent anovulation. The incidence of PCOS is as high as 5 % \~ 10 % in women of childbearing age \[[@CR1]\] (the prevalence is 5.61 % in Chinese women of childbearing age \[[@CR2]\]), and it mainly manifests as oligomenorrhea/amenorrhea (O), oligoovulation/anovulation (O), and acne, etc., as well as obesity, hirsutism, and polycystic ovary (PCO), etc. Since 1990s, three diagnostic criteria have appeared for PCOS: Maryland diagnosis consensus developed by National Institutes of Health (NIH) in 1990, Rotterdam diagnosis criteria developed by European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM) in 2003, and diagnosis criteria developed by Androgen Excess Society (AES) in 2006. Studies revealed different degrees of obesity, dyslipidemia, insulin resistance (IR), abnormal glucose metabolism, metabolic syndrome (MetS), and other metabolic abnormalities \[[@CR2], [@CR3]\] in PCOS patients. As one of the most important clinical features of PCOS, hyperandrogenism (HA) tends to cause IR, where the free androgen level is generally higher and the IR extent is also significantly aggravated in females with central obesity compared with normal control group. Different possible mechanisms were reported in various studies, which included the following: The androgen may directly or indirectly affect the glucose metabolism, thereby leading to HA. Second, the androgen may directly inhibit the effects of peripheral and intrahepatic insulin and cause HA. Furthermore, the androgen may increase the formation of free fatty acids, inhibit clearance of intrahepatic insulin, causing HA, thereby resulting in IR and metabolic abnormalities. This study aimed to identify the effect of the presence of HA on metabolic abnormalities in PCOS patients using systematic review and meta-analysis, thereby to provide reference for further in-depth studies, as well as to provide a basis for the treatment and prevention of long-term complications in PCOS patients.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Studies published between January 1980 and November 2014 were searched, where the computerized databases Medline, PubMed, Embase, Cochrane Library, and Web of Science were searched to identify eligible studies in English-language journals, while the computerized databases such as Chinese Biomedical Database, China National Knowledge Infrastructure (CNKI), Wanfang database, and VIP Information/Chinese Scientific Journals Database were searched for Chinese-language journals, and manual search or literature recall were supplemented. Keywords for the search included "polycystic ovary syndrome," "hyperandrogenism," "metabolic diseases," and "metabolic syndrome," etc.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Inclusion criteria: (1) Observation studies including cohort studies, case--control studies, and cross-sectional studies; (2) PCOS patients with or without HA, or PCOS patients with different phenotypes, the diagnosis of which abided by the 2003 Rotterdam criteria or 2006 AES criteria; and (3) studies with primary outcomes including the incidence of MetS, insulin resistance indexes including homeostasis model assessment for insulin resistance (HOMA-IR) and incidence of IR, and lipid metabolism indexes including total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).

Exclusion criteria:(1) Repeated and/or irrelevant literature, or literature with incomplete information; conference abstracts without detailed contents; academic dissertation; and literature review; (2) control group, or any unreasonable design, inexactor contradictory experimental results; (3) studies not stating clear diagnostic criteria for PCOS or adopting 1990 diagnostic criteria for PCOS issued by NIH; (4) studies not comparing the metabolism between PCOS patients with and without HA, or the metabolism among patients with different PCOS phenotypes; (5) studies not involving outcomes; and (6) if the same agency published a number of articles with overlapping time span, earlier studies were excluded while only the latest literature was retained.

Literature filtering, data extraction, and quality assessment {#Sec5}
-------------------------------------------------------------

The articles were filtered, data were extracted, and methodological quality was assessed independently by two investigators. Any discrepancy was resolved by discussion or by a third party until a consensus was reached. Data were extracted according to a predesigned table, including general characteristics, type of studies, subjects, factors, and outcomes, etc. PCOS was diagnosed according to different classifications, where PCO + O + HA, PCO + HA, and HA + O were merged as the HA group, and PCO + O was considered as non-HA group of the PCOS.

The Newcastle--OttawaScalewas \[[@CR4]\] used to assess the quality of the cohort studies and case--control studies. Quality assessment criteria recommended by the Agency for Healthcare Research and Quality (AHRQ) \[[@CR5]\] was used to assess the quality of cross-sectional studies, of which only the former 10 items were selected, since the 11th item was not suitable for assessing the cross-sectional studies, each of which was scored "yes," "no," or "unclear." Quality was assessed independently by two investigators, and any discrepancy was resolved by discussion or by three other authors in this study.

Statistical analysis {#Sec6}
--------------------

Meta-analysis was performed using the Stata 12.0 software. Categorical variables were expressed as odds ratio and 95 % confidence interval (95%CI). Continuous variables were expressed as mean difference or standardized mean difference (SMD) and 95%CI. The enrolled articles were tested for heterogeneityusing the*χ* ^*2*^ test, with an inspection level *α* = 0.1 or *P* ≤ 0.1, and the results of various articles were found to be heterogeneous. Heterogeneity was assessed using*I* ^2^, where *I* ^2^ ≥ 25 %, *I* ^2^ ≥ 50 %, and *I* ^2^ ≥ 75 % referred to a low, moderate, and high degree of heterogeneity, respectively. If there was no heterogeneity among various studies, the meta-analyses were performed using a fixed-effect model. Otherwise, meta-analyses were performed using a random effect model, and the source of the heterogeneity was further analyzed and possible factors were performed subgroup analyses, of which description analyses were adopted if there existed excessive heterogeneity between the two groups or it was impossible to find the data resources. A difference with *P* \< 0.05 was considered statistically significant. Then, sensitivity analyses were conducted by excluding the impact of individual study one by one on the overall results of the analysis. Moreover, publication bias was quantitatively assessed using the funnel plot and Egger test.

Results {#Sec7}
=======

Literature search results {#Sec8}
-------------------------

A total of 4457 articles were preliminarily searched, and ultimately 32 articles were included after layer-by-layer screening \[[@CR6]--[@CR37]\]. The screening flowchart and results are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart demonstrating study selection

Characteristics and quality assessment of the included studies {#Sec9}
--------------------------------------------------------------

The 32 articles included were cross-sectional studies, involving 9556 patients, of which 6482 cases were in the HA group and 3074 cases in the non-HA group. The basic characteristics and quality assessment of the included studies are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Characteristics of included studiesIncluded studiesLocationSample size (hyperandrogenemia/nonhyperandrogenemia)Mean age (range, year)PCOS diagnostic criteriaType of studyExtracted index^j^Hosseinpanah 2014 \[[@CR6]\]Iran136 (109/27)33.6 (18 \~ 45)2003 Rotterdam criteriaCross-sectional^b, d, f^Kim 2014 \[[@CR7]\]Korea700 (432/268)27.9 (15 \~ 40)2003 Rotterdam criteriaCross-sectional^a^Lerchbaum 2014 \[[@CR8]\]Austria706 (352/354)27^h^ (16 \~ 45)2003 Rotterdam criteriaCross-sectional^a, b^Livadas 2014 \[[@CR9]\]Greece1218 (716/502)23^h^2003 Rotterdam criteriaCross-sectional--Sung 2014 \[[@CR10]\]Korea1062 (645/417)242003 Rotterdam criteriaCross-sectional^a, c, d, e, f^Tehrani 2014 \[[@CR11]\]Iran85 (72/13)29.07 (18 \~ 45)2003 Rotterdam criteriaCross-sectional^a, c, d, e, f, g^Ates 2013 \[[@CR12]\]Turkey410 (334/76)24.552003 Rotterdam criteriaCross-sectional^a, c, e, f, g^Di Sarra 2013 \[[@CR13]\]Italy89 (65/24)23.6 (18 \~ 40)2003 Rotterdam criteriaCross-sectional^d, e, f, g^Zhu 2013 \[[@CR14]\]Shanghai, China53 (28/25)22.822003 Rotterdam criteriaCross-sectional^d, e, f, g^Gluszak 2012 \[[@CR15]\]Poland93 (88/5)23.952003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Jones 2012 \[[@CR16]\]United Kingdom29 (19/10)282003 Rotterdam criteriaCross-sectional--Li 2012 \[[@CR17]\]Guangdong, China131 (62/69)29.572003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Ozkaya 2012 \[[@CR18]\]Turkey132 (100/32)24.212003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Cupisti 2011^i^ \[[@CR19]\]Germany309 (293/16)27.162006AES criteria^i^Cross-sectional^c, d, e, f, g^Mehrabian 2011 \[[@CR20]\]Iran539 (287/252)29.3 (18 \~ 42)2003 Rotterdam criteriaCross-sectional^a, b, c, f^Melo 2011 \[[@CR21]\]Brazil226 (175/51)26.452003 Rotterdam criteriaCross-sectional^a, c, d, e, f, g^Wijeyaratne 2011 \[[@CR22]\]Sri Lanka469 (374/95)252003 Rotterdam criteriaCross-sectional^a^Yilmaz 2011 \[[@CR23]\]Turkey127 (103/24)25.36 (18 \~ 35)2003 Rotterdam criteriaCross-sectional^a, c, d, e, f, g^Castelo-Branco 2010 \[[@CR24]\]Spain197 (152/45)28.42003 Rotterdam criteriaCross-sectional^e, f, g^Guo 2010 \[[@CR25]\]Shandong, China615 (571/44)28.3 (20 \~ 41)2003 Rotterdam criteriaCross-sectional^a, c, d, e, f, g^Goverde 2009 \[[@CR26]\]Netherlands157 (101/56)29 (17 \~ 43)2003 Rotterdam criteriaCross-sectional^a, b, c, f^Barber 2007 \[[@CR27]\]United Kingdom309 (267/42)33.262003 Rotterdam criteriaCross-sectional^a^Shroff 2007 \[[@CR28]\]United States258 (224/34)27.86 (18 \~ 45)2003 Rotterdam criteriaCross-sectional^a, c, d, e, f, g^Chen H 2014 \[[@CR29]\]Shanghai, China126 (34/92)272003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Li YC 2014 \[[@CR30]\]Guangxi, China68 (42/26)25.51 (18 \~ 37)2003 Rotterdam criteriaCross-sectional^d, e, f, g^Ha LX 2013 \[[@CR31]\]Ningxia, China267 (127/140)25.212003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Tao T 2013 \[[@CR32]\]Shanghai, China305 (248/57)26.44 (18 \~ 45)2003 Rotterdam criteriaCross-sectional^a^Li J 2011 \[[@CR33]\]Shanghai, China95 (84/11)Unknown2003 Rotterdam criteriaCross-sectional^c, d, e, f, g^Liu L 2011 \[[@CR34]\]Zhejiang, China48 (34/14)27.15 (23 \~ 33)2003 Rotterdam criteriaCross-sectional^d, e, f, g^Qu ZY 2011 \[[@CR35]\]Shandong, China306 (177/129)Unknown2003 Rotterdam criteriaCross-sectional^b^Xu LS 2010 \[[@CR36]\]Tianjin, China256 (152/104)23.8 (14 \~ 39)2003 Rotterdam criteriaCross-sectional^b, c^Zhang L 2010 \[[@CR37]\]Jiangsu, China35 (15/20)29.43 (21 \~ 35)2003 Rotterdam criteriaCross-sectional^ba^Number of cases with MetS; ^b^Number of cases with IR; ^c^HOMA-IR value; ^d^TC value; ^e^TG value; ^f^HDL value; ^g^LDL value; ^h^Median; ^i^PCOS typing had10 subtypes, and the rest had four subtypes; ^j^Meant that the corresponding outcome data were not exactable if they were data of median or quartiles that could not be converted into mean ± standard deviation Table 2Methodological quality assessment of the included cross-sectional studiesIncluded studiesQ1Q2Q3Q4Q5Q6Q7Q8Q9Q10Hosseinpanah 2014 \[[@CR6]\]YesYesYesYesUnclearYesNoNoNoYesKim 2014 \[[@CR7]\]YesYesYesUnclearUnclearYesNoYesNoNoLerchbaum 2014 \[[@CR8]\]YesYesYesUnclearUnclearYesNoNoNoYesLivadas 2014 \[[@CR9]\]YesYesYesYesUnclearYesNoYesNoYesSung 2014 \[[@CR10]\]YesYesYesUnclearUnclearYesNoYesNoYesTehrani 2014 \[[@CR11]\]YesYesYesYesUnclearYesNoNoNoYesAtes 2013 \[[@CR12]\]YesYesYesUnclearUnclearYesNoNoNoYesDi Sarra 2013 \[[@CR13]\]YesYesNoUnclearUnclearNoNoNoNoYesZhu 2013 \[[@CR14]\]YesYesYesUnclearUnclearYesNoYesNoYesGluszak 2012 \[[@CR15]\]NoYesNoUnclearUnclearNoNoNoNoYesJones 2012 \[[@CR16]\]NoYesNoUnclearUnclearYesNoNoNoYesLi 2012 \[[@CR17]\]NoYesNoUnclearUnclearYesNoNoNoYesOzkaya 2012 \[[@CR18]\]YesYesYesYesUnclearYesNoNoNoYesCupisti 2011 \[[@CR19]\]NoYesYesUnclearUnclearYesNoNoNoNoMehrabian 2011 \[[@CR20]\]YesYesYesUnclearUnclearYesNoNoNoYesMelo 2011 \[[@CR21]\]YesYesYesYesUnclearYesNoNoNoYesWijeyaratne 2011 \[[@CR22]\]YesYesYesYesUnclearYesNoNoNoNoYilmaz 2011 \[[@CR23]\]YesYesYesUnclearUnclearNoNoNoNoYesCastelo-Branco 2010 \[[@CR24]\]NoYesYesYesUnclearYesNoNoNoYesGuo 2010 \[[@CR25]\]YesYesYesUnclearUnclearYesNoNoNoYesGoverde 2009 \[[@CR26]\]YesYesNoUnclearUnclearYesNoNoNoNoBarber 2007 \[[@CR27]\]YesYesNoUnclearUnclearYesNoNoNoNoShroff 2007 \[[@CR28]\]YesYesYesUnclearUnclearNoNoYesNoYesChen H 2014 \[[@CR29]\]YesYesYesUnclearUnclearYesNoNoNoYesLi YC 2014 \[[@CR30]\]YesYesYesUnclearUnclearYesNoNoNoYesHa LX 2013 \[[@CR31]\]YesYesYesUnclearUnclearYesNoNoNoYesTao T 2013 \[[@CR32]\]YesYesYesUnclearUnclearYesNoNoNoYesLi J 2011 \[[@CR33]\]YesYesYesUnclearUnclearYesNoNoNoYesLiu L 2011 \[[@CR34]\]YesYesYesUnclearUnclearYesNoNoNoNoQu ZY 2011 \[[@CR35]\]YesYesYesUnclearUnclearYesNoNoNoYesXu LS 2010 \[[@CR36]\]YesYesYesUnclearUnclearYesNoNoNoYesZhang L 2010 \[[@CR37]\]YesYesYesUnclearUnclearYesNoNoNoYesAHRQ was used to assess the quality of the cross-sectional studies---Q1:whether there was a clear source of data (surveys, literature review);Q2:whether the inclusion and exclusion criteria of the exposure or nonexposure groups (case and control groups) were listed or referred to as previous literature;Q3:whether the period of time to identify patients was provided;Q4:for subjects who did not come from the crowd, whether they were continuously observed;Q5:whether the other aspects of the subjects were overshadowed by the subjective factors of the evaluators;Q6:whether any evaluation to ensure the quality was described (such as test/retest of the primary outcomes);Q7:whether the reasons to exclude any patient were provided;Q8:whether the measures to evaluate and control confounding factors were described;Q9:if possible, whether the studies explain how to handle the missing data;Q10:whether the studies summarized the response rate of the patients and the integrity of data collection

Meta-analysis results {#Sec10}
---------------------

### Incidence of metabolic syndrome {#Sec11}

Among the enrolled articles, the incidence of MetS was involved in 14 studies \[a total of 5968 PCOS patients, including 4185 cases in the PCOS patients with HA (PCOS/HA) group and 1783 cases in the PCOS patients without HA (PCOS/NHA group)\] \[[@CR8], [@CR9], [@CR11]--[@CR13], [@CR21]--[@CR24], [@CR26]--[@CR29], [@CR33]\]. Since results of different studies were heterogeneous (*P* = 0.020, *I* ^2^ = 48.9 %), OR was combined using Peto method for meta-analysis, and the results revealed that the incidence of MetS showed statistical significance between the PCOS/HA and the PCOS/NHA groups \[Peto OR = 2.21, 95 % CI(1.88,2.59), *P* \< 0.001 (Fig. [2](#Fig2){ref-type="fig"})\]. Then sensitivity analyses were performed after excluding one study with large heterogeneity, and the results revealed that the combined effect quantity was still of statistical significance and no changes occurred in the forest map structure.Fig. 2Meta-analysis for the effects of HAon the incidence of MetS in PCOS patients

### HOMA-IR {#Sec12}

HOMA-IR was mentioned in 17 out of the included articles \[[@CR11]--[@CR13], [@CR16], [@CR18]--[@CR22], [@CR24], [@CR26], [@CR27], [@CR29], [@CR30], [@CR32], [@CR34], [@CR37]\] (a total of 4888 PCOS patients, including 3452 cases in the PCOS/HA group and 1436 cases in the PCOS/NHA group). Since results of different studies were heterogeneous (*P* \< 0.001, *I* ^2^ = 79.1 %), the random effect model was used for meta-analysis and the results showed that the difference of HOMA-IR was statistically significant between the PCOS/HA and PCOS/NHA groups \[SMD = 0.28, 95 % CI (0.11,0.44), *P* = 0.001 (Fig. [3](#Fig3){ref-type="fig"})\].Fig. 3Meta-analysis for effects of HAon HOMA-IR in PCOS patients

### Incidence of insulin resistance {#Sec13}

Incidence of IR was involved in eight \[[@CR7], [@CR9], [@CR21], [@CR27], [@CR35]--[@CR37]\] out of the included articles (a total of 2183 patients, including 1227 cases in the PCOS/HA group and 956 cases in the PCOS/NHA group). Since results of different studies were heterogeneous (*P* = 0.003, *I* ^2^ = 67.3 %), the random effect model was adopted for meta-analysis, and the results revealed that the incidence of IR was statistically significant between the PCOS/HA and PCOS/NHA groups \[OR = 3.11, 95 % CI(2.32,4.17), *P* \< 0.001 (Fig. [4](#Fig4){ref-type="fig"})\].Fig. 4Meta-analysis for the effects of HA on the incidence of IR in PCOS patients

### Lipid metabolism {#Sec14}

Lipid metabolism indexes included total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).*Total cholesterol*TC was involved in 18 \[[@CR7], [@CR11], [@CR12], [@CR14]--[@CR16], [@CR18]--[@CR20], [@CR22], [@CR24]--[@CR26], [@CR29]--[@CR32], [@CR34], [@CR35]\] out of the included articles (a total of 3920 PCOS patients, including 2856 cases in the PCOS/HA group and 1064 cases in the PCOS/NHA group). Meta-analysis was performed using the random effect model due to heterogeneity among different studies (*P* = 0.002, *I* ^2^ = 56.6 %), and the results showed that the difference of TC was not statistically significant between the PCOS/HA and PCOS/NHA groups \[SMD = 0.05, 95 % CI (−0.09,0.18), *P* = 0.494\].*Triglycerides*TG was involved in 19 \[[@CR11]--[@CR16], [@CR18]--[@CR20], [@CR22], [@CR24]--[@CR26], [@CR29]--[@CR32], [@CR34], [@CR35]\] out of the included articles (a total of 4391 PCOS patients, including 3233 cases in the PCOS/HA group and 1158 cases in the PCOS/NHA group). Meta-analysis was conducted using the random effect model due to heterogeneity among different studies (*P* \< 0.001, *I* ^2^ = 72.7 %), which revealed that the difference of TG was statistically insignificant between the PCOS/HA and PCOS/NHA groups \[SMD = 0.15, 95 % CI (−0.01, 0.31), *P* = 0.061\].*High-density lipoprotein*HDL was involved in 22 \[[@CR7], [@CR11]--[@CR16], [@CR18]--[@CR22], [@CR24]--[@CR27], [@CR29]--[@CR32], [@CR34], [@CR35]\] out of the included articles (a total of 5223 PCOS patients, including 3730 cases in the PCOS/HA group and 1493 cases in the PCOS/NHA group). Also, meta-analysis was conducted using the random effect model due to heterogeneity among different studies (*P* \< 0.001, *I* ^2^ = 80.9 %), which showed that the difference of HDL was statistically significant between the PCOS/HA and PCOS/NHA groups \[SMD = -0.22, 95 % CI (-0.39,-0.06), *P* = 0.009\].*Low-density lipoprotein*LDL was mentioned in 18 \[[@CR12]--[@CR16], [@CR18]--[@CR20], [@CR22], [@CR24]--[@CR26], [@CR29]--[@CR32], [@CR34], [@CR35]\] out of the included articles (a total of 3329 PCOS patients, including 2588 cases in the PCOS/HA group and 741 cases in the PCOS/NHA group). Again, meta-analysis was conducted using the random effect model due to heterogeneity among different studies (*P* \< 0.001, *I* ^2^ = 66.0 %), which revealed that the difference of LDL was statistically insignificant between the PCOS/HA and PCOS/NHA groups \[SMD = 0.14, 95 % CI (−0.03,0.30), *P* = 0.106\].

Publication bias {#Sec15}
----------------

Publication bias was analyzed using the funnel plot, and the results revealed a good symmetric distribution of the included studies on both sides of the funnel plot, suggesting a small possibility of publication bias. Also, publication bias was not found in further Egger test (*P* = 0.820) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Funnel Plot analysis of publication bias of impact of hyperandrogenemia on the incidence of metabolic syndrome in PCOS patients

Discussions {#Sec16}
===========

A total of 32 articles were included in this systematic assessment, and the meta-analysis revealed that the incidence of MetS, HOMA-IR value, incidence of IR were higher in the PCOS/HA group compared with the PCOS/NHA group, and the HDL value in the PCOS/HA group was smaller than that in the PCOS/NHA group, while TC, TG, and LDL were not significantly different between the PCOS/HA and PCOS/NHA groups. The included 32 articles were cross-sectional studies, with a large sample size and ordinary quality. Sensitivity and publication bias analyses showed stable meta-analysis results, while there existed a large heterogeneity among the studies, which might affect the results.

Limitations of this study included the following: (1) All the included articles were cross-sectional studies, and there was a lack of cohort studies and case--control studies, presenting a low argumentation intensity. (2) All the included articles were published literature, and there was a lack of gray literature, which might lead to publication bias. (3) This study failed to conduct subgroup analyses in patients from different regions, hereby the bias caused by population factors from different regions could not be excluded. (4) In most of the included studies, important confounding factors such as age, body mass index (BMI), waistline and waist--hipratio, etc., were not adjusted. However, metabolic abnormalities might be different among patients with different ages, BMIs, waistlines, and waist--hipratios, which are prone to affect the meta-analysis results. (5) There was a large heterogeneity among studies, which might affect the meta-analysis results.

Conclusions {#Sec17}
===========

HA play a role between PCOS and MetS. There were differences in HOMA-IR and IR incidence between PCOS/HA and PCOS/NHA; also the lipid metabolism might present a trend of variation between PCOS/HA and PCOS/NHA patients. However, due to the limitations of sample size and quality, the present-study conclusions require further verification using a larger sample size and high-quality studies.
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